Addex to Host R&D Day on July 16>
Addex to Host R&D Day on July 16
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Geneva, Switzerland, 2 July 2009 - Allosteric modulation companyAddex Pharmaceuticals (SIX:ADXN) invites investors, analysts, mediaand other interested parties to attend its annual R&D day onThursday, July 16, 2009 in Geneva, Switzerland.Addex management will discuss advances made with its small moleculeallosteric modulator drug discovery platform as well as the status ofmultiple drug candidates, including the clinical-stage productsADX10059, ADX48621 and ADX71149, which are in development forgastroesophageal reflux disease (GERD), migraine prevention,Parkinson's disease, schizophrenia and anxiety. Addex also willdisclose new early stage programs for important indications inmetabolic disease and inflammation. What: Addex Pharmaceuticals R&D Day When: 11:00am CET to 3:30pm CET, July 16,2009 Where: 14, Chemin des Aulx 1228 Plan-les-Ouates, Geneva SwitzerlandInterested parties are encouraged to attend in person. A completeprogram will be made available on our website prior to the event.Please email investor.relations(at)addexpharma.com ormedia.relations(at)addexpharma.com for more information.The Addex R&D Day presentations, related question and answer sessionsand supporting documents will be webcast live and made availablethereafter via www.addexpharma.com.Addex Pharmaceuticals (www.addexpharma.com) discovers and developsallosteric modulators for human health. Allosteric modulators are adifferent kind of orally available small molecule therapeutic agent,which we believe will offer a competitive advantage over classicaldrugs. Our lead allosteric modulator product, ADX10059, has achievedclinical proof of concept and is in Phase IIb testing for thetreatment of GERD and, separately, migraine headache. Both areimportant diseases for which existing products with limited efficacyhave established multi-billion dollar markets despite sub-optimalefficacy. ADX10059 is a first-in-class mGluR5 inhibitor, atherapeutic strategy that also is being pursued in multipleindications by large pharma competitors.Our products and technology already have proven their value throughour partnerships with four of the top 10 pharmaceutical companies inthe world. Specifically, an agreement with Ortho-McNeil-Janssen Inc.is focused on development of allosteric modulators to treat anxietyand schizophrenia. In addition, in two separate agreements with Merck& Co., Inc., we are developing allosteric modulators as drugs totreat Parkinson's disease and schizophrenia, respectively. Finally,GlaxoSmithKline and Roche have made equity investments in Addex.Chris MaggosHead of IR & CommunicationsAddex Pharmaceuticals+41 22 884 15 11chris.maggos(at)addexpharma.comDisclaimerThe foregoing release may contain forward-looking statements that canbe identified by terminology such as "not approvable", "continue","believes", "believe", "will", "remained open to exploring", "would","could", or similar expressions, or by express or implied discussionsregarding Addex Pharmaceuticals Ltd, its business, the potentialapproval of its products by regulatory authorities, or regardingpotential future revenues from such products. Such forward-lookingstatements reflect the current views of Addex Pharmaceuticals Ltdregarding future events, future economic performance or prospects,and, by their very nature, involve inherent risks and uncertainties,both general and specific, whether known or unknown, and/or any otherfactor that may materially differ from the plans, objectives,expectations, estimates and intentions expressed or implied in suchforward-looking statements. Such may in particular cause actualresults with allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7or other therapeutic targets to be materially different from anyfuture results, performance or achievements expressed or implied bysuch statements. There can be no guarantee that allosteric modulatorsof mGluR2, mGluR4, mGluR5, mGluR7 will be approved for sale in anymarket or by any regulatory authority. Nor can there be any guaranteethat allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 or othertherapeutic targets will achieve any particular levels of revenue (ifany) in the future. In particular, management's expectationsregarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 orother therapeutic targets could be affected by, among other things,unexpected actions by our partners, unexpected regulatory actions ordelays or government regulation generally; unexpected clinical trialresults, including unexpected new clinical data and unexpectedadditional analysis of existing clinical data; competition ingeneral; government, industry and general public pricing pressures;the company's ability to obtain or maintain patent or otherproprietary intellectual property protection. Should one or more ofthese risks or uncertainties materialize, or should underlyingassumptions prove incorrect, actual results may vary materially fromthose anticipated, believed, estimated or expected. AddexPharmaceuticals Ltd is providing the information in this pressrelease as of this date and does not undertake any obligation toupdate any forward-looking statements contained in this press releaseas a result of new information, future events or otherwise, except asmay be required by applicable laws. --- End of Message ---Addex Pharmaceuticals12, chemin des Aulx Plan-les-Ouates, Geneva SwitzerlandISIN: CH0029850754; Index: SLIFE, SPI, SPIEX, SSCI;Listed: Main Market in SIX Swiss Exchange;
" alt="Correction: Issue of equity and total voting rights>">
" alt="SDRL - Seadrill dispose of the jack-up rig West Ceres>">
Datum: 03.07.2009 - 12:00 Uhr
Sprache: Deutsch
News-ID 3224
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 301 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex to Host R&D Day on July 16>"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
